Identification and targeting of protein tyrosine kinase 7 (PTK7) as an immunotherapy candidate for neuroblastoma

Area of Science:

• Immunology
• Oncology
• Biochemistry

Background:

• GD2-targeting immunotherapies have improved neuroblastoma survival but face challenges with toxicity and treatment resistance.
• Many neuroblastoma patients previously received chemotherapy, necessitating antigens stable under such conditions.
• Protein tyrosine kinase 7 (PTK7) was identified as a potential neuroblastoma-specific antigen post-chemotherapy.

Purpose of the Study:

• To evaluate protein tyrosine kinase 7 (PTK7) as a target for neuroblastoma immunotherapy.
• To assess the preclinical efficacy and safety of PTK7-targeting chimeric antigen receptor (CAR) T-cells.

Main Methods:

• Cell surface glycoproteomics on human neuroblastoma tumors in mice post-chemotherapy.
• Development of an anti-PTK7 CAR T-cell therapy.
• In vitro and in vivo testing of PTK7 CAR T-cells against neuroblastoma models.

Main Results:

• PTK7 is abundantly expressed on neuroblastoma tumors and minimally on normal pediatric tissues.
• PTK7 CAR T-cells specifically targeted and killed PTK7-expressing neuroblastoma in vitro.
• PTK7 CAR T-cells demonstrated efficacy in regressing aggressive neuroblastoma and prolonging survival in vivo without toxicity.

Conclusions:

• PTK7 is a viable and safe target for neuroblastoma immunotherapy.
• PTK7-targeting CAR T-cells show significant preclinical efficacy and tolerability.
• Further optimization of PTK7 CAR T-cells is warranted for clinical application in neuroblastoma treatment.